Verdict
MIXED
MIXED — Casgevy became the first FDA-authorized CRISPR-based gene-editing therapy in the United States on December 8, 2023, But Not Completely
Verified on July 20, 2026
Other elements remain incomplete or inconsistently documented across the cited sources.
Confidence58%
How strongly independent, cited sources support this verdict.
Claim reviewed
Casgevy became the first FDA-authorized CRISPR-based gene-editing therapy in the United States on December 8, 2023.
Analysis summary
other elements remain incomplete or inconsistently documented across the cited sources.
Evidence profile
60 / 100 weighted evidence score
H:2 / M:0 / L:1
Key findings
- other elements remain incomplete or inconsistently documented across the cited sources.
Sources
Analyzed across 3 independent publishers
FDA Approves First Gene Therapies to Treat Patients with ...
Fda
High credibility
78/100
government_primaryInstitutional domain
FDA approves CASGEVY, the first CRISPR/Cas9 gene ... - PMC
Nih
High credibility
78/100
government_primaryInstitutional domain
FDA Approves Casgevy, the First CRISPR Therapy, for ...
Genengnews
Low credibility
24/100
unknown_low_authorityStandard web source
Citations
Copy formatted citations from the verified sources above.
Need to verify another claim?
Open Claims Radar to analyze headlines, posts, or links with live source checks.
Verify a claim
Verified by
Claims Radar
Possum Mattern Studios
Possum Mattern Studios